Monopar Therapeutics (MNPR) expects to raise $40 million in an initial public offering (IPO) on Tuesday, October 1st, IPO Scoop reports. The company plans to issue 4,400,000 shares at $8.00-$10.00 per share.
Monopar Therapeutics has a market-cap of $267.4 million.
JonesTrading acted as the underwriter for the IPO.
Monopar Therapeutics provided the following description of their company for its IPO: ” We are a clinical stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. We are building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. We leverage our scientific and clinical experience to help de-risk and accelerate the clinical development of our drug product candidates. We intend to begin a Phase 3 clinical development program for our lead product candidate, Validive (clonidine mucobuccal tablet; clonidine MBT), in the fourth quarter of 2019. “.
Monopar Therapeutics was founded in 2014 and has 5 employees. The company is located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, US and can be reached via phone at (847) 388-0349 or on the web at http://www.monopartx.com.
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.